Impact of Pretransplant Malignancy on Heart Transplantation Outcomes: Contemporary United Network for Organ Sharing Analysis Amidst Evolving Cancer Therapies

Background: An aging population and improved cancer survivorship have increased the number of individuals with treated malignancy who develop advanced heart failure. The benefits of heart transplantation (HT) in patients with a pretransplant malignancy (PTM) must be balanced against risks of posttransplant malignancy in the setting of immunosuppression. Methods: Adult patients in the United Network for Organ Sharing registry who received HT between January 1, 2010, and December 31, 2020 were included. Trends, patient characteristics, and posttransplant outcomes in HT recipients with PTM were evaluated. Results: From 2000 to 2020, the proportion of HT recipients with PTM increased from 3.2% to 8.2%. From 2010 to 2020, 2113 (7.7%) of 27 344 HT recipients had PTM. PTM was associated with higher rates of 1-year mortality after HT (11.9% versus 9.2%; adjusted hazard ratio, 1.25 [95% CI, 1.09–1.44], P=0.001), driven by increased mortality in patients with hematologic PTM (adjusted hazard ratio, 2.00 [95% CI, 1.61–2.48]; P<0.001). For recipients who survived the first year, 5-year survival was similar between patients with and without PTM. Rates of malignancy at 5-years posttransplant were higher in the PTM group (20.4% versus 13.1%; adjusted hazard ratio, 1.57 [95% CI, 1.38–1.79], P<0.001). Conclusions: Prevalence of PTM in HT recipients nearly tripled over the past 2 decades. Patients with hematologic PTM were at increased risk of early mortality after HT. Patients with PTM were also at higher risk for posttransplant malignancy. Guidelines that reflect contemporary oncological care are needed to inform care of this heterogenous and expanding group of individuals.

[1]  N. Dowling,et al.  Predicted Heart Age Among Cancer Survivors — United States, 2013–2017 , 2021, MMWR. Morbidity and mortality weekly report.

[2]  P. Bierman,et al.  Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  P. Bierman,et al.  Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  J. Herrmann Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia , 2020, Nature Reviews Cardiology.

[5]  L. Wilke,et al.  Impact of Pre-Transplant Malignancy on Outcomes After Kidney Transplantation: United Network for Organ Sharing Database Analysis. , 2019, Journal of the American College of Surgeons.

[6]  Ahmedin Jemal,et al.  Cancer treatment and survivorship statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[7]  S. Kim,et al.  Solid Organ Transplantation in Patients With Preexisting Malignancies in Remission: A Propensity Score Matched Cohort Study , 2018, Transplantation.

[8]  F. Granath,et al.  Overall and Cause-Specific Mortality in Transplant Recipients with a Pretransplantation Cancer History , 2013, Transplantation.

[9]  J. Conte,et al.  Pre-transplant malignancy: an analysis of outcomes after thoracic organ transplantation. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[11]  J. Grinyó,et al.  Malignancy after renal transplantation: the role of immunosuppression , 2010, Nature Reviews Nephrology.

[12]  Michael S Ewer,et al.  Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. , 2004, Circulation.

[13]  B. Kasiske,et al.  The evaluation of renal transplantation candidates: clinical practice guidelines. , 2001, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  Á. Gutiérrez-Dalmau,et al.  Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients , 2012, Drugs.